[206 Pages Report] Rising at a CAGR of 5.6% from 2022 to 2029, arthropod-borne viral infections testing demand is estimated to attain a valuation of US$ 1.3 Bn by end of the forecast period. The global Arthropod-Borne Viral Infections Testing Market is worth US$ 1.9 Bn in 2022.
| Attribute | Details |
|---|---|
| Arthropod-borne Viral Infections Testing Market Size (2022) | US$ 1.3 Bn |
| Predicted Net Worth (2029) | US$ 1.9 Bn |
| Global Market Growth Metrics (2022-2029) | 5.6% CAGR |
| Market Share of ELISA-based Tests | 52% |
Arboviral diseases are infections caused by virus spread among humans through the bites of arthropods. Common arthropods through which diseases are spread are mosquitoes and ticks. Arthropod-borne viral infections testing accounts for 4.4% of the global infectious disease diagnostics market, which stood at US$ 28 Bn in 2021.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Particulars | Details |
|---|---|
| H1, 2021 | 5.64% |
| H1, 2022 Projected | 5.63% |
| H1, 2022 Outlook | 3.83% |
| BPS Change - H1, 2022 (O) – H1, 2022 (P) | (-) 180 ↓ |
| BPS Change – H1, 2022 (O) – H1, 2021 | (-) 181 ↓ |
The variation between the BPS values observed within the arthropod-borne viral infections testing market in H1, 2022 - outlook over H1, 2022 projected reflects a decline by 180 BPS units. Additionally, a value BPS decline in H1-2022 over H1-2021 by 181 Basis Point Share (BPS) is demonstrated by the market.
The market observes a decline in the BPS values owed to the poor accessibility of detection methods in low-income economies with a large disease burden. As a result, high costs of healthcare facilities along with a lack of awareness about infectious diseases are expected to restrain the market's growth.
The market is subjected to several macro economical and industry variables, which include disease epidemiology, biologics licensing, product patenting and distribution licensing. Factors such as climate change, urbanization, and global trade can expand the geographic distribution of vectors and associated arboviruses, thus increasing the potential disease burden in susceptible hosts. This factor can present an opportunity for a positive growth outlook for the market
Healthcare has become an area of prime concern across the world and this is due to the rising diseases and infections across the world. There has been a substantial rise in arboviral diseases over the past few years and this has influenced demand for arthropod-borne viral infections testing.
Arthropod-borne viral infections testing demand rose at a CAGR of 4.9% from 2014 to 2021 and ended up with a market worth of US$ 1.2 Bn in 2021.
Most common arthropod-borne viral infection in the world according to WHO (World Health Organization) is dengue, with the potential risk to infect more than 30% of the world’s population.
Rising focus on public healthcare, increasing travel and trade activities on a global scale, changing lifestyle trends, environmental and climatic changes, rapid urbanization across the world, etc. are some major factors that influence arthropod-borne viral infections testing market potential on a global scale.
The market for arthropod-borne viral infections testing is anticipated to rise at a CAGR of 5.6% over the forecast period of 2022 to 2029.
“Re-emergence of Arthropod-borne Viral Infections to Drive Demand”
Arthropod-borne infections have proven to be responsible for widespread epidemics across the world. Some of the notable arboviral epidemics are of dengue and Zika virus which led to further complications in the population infected.
These epidemics have been dealt with to a certain extent but have proven their re-emergence in recent times which is a major factor that drives demand for arthropod-borne viral infections testing on a global level. The unpredictable nature of these infections promotes arthropod-borne viral infections testing providers to develop better diagnostic solutions to detect and avoid a community spread of these infections.
“Increasing Government Initiatives to Limit Risk of Arboviral Infections”
Governments across the world are working in sync with health organizations to mitigate the risk of arthropod-borne viral infections. As a matter of public safety, the focus on these diseases is increasing in the past few years with severe outbreaks being recorded across the world. The emergence of coronavirus in 2020 has further bolstered the importance of government inclusion in matters of public health.
“MEA and Latin America to Provide Major Opportunities for Market Players”
This FMI industry analysis provides metrics for the arthropod-borne viral infections testing market across regions such as North America, Latin America, Europe, East Asia, South Asia & Pacific, and the Middle East & Africa (MEA).
The market for arthropod-borne viral infections testing in Latin America is anticipated to see high demand over the forecast period as it accounts for a notable number of infections across the world.
Developing healthcare infrastructure and rising awareness about arthropod-borne infections is anticipated to influence arthropod-borne viral infections testing demand in this region.
Demand for arthropod-borne viral infections testing in North America is expected to be low as the incidence of arboviral infections and diseases in this region is low. Advanced healthcare infrastructure and proper preventive care reduce the chances of infection in this region.
East Asia and South Asia are expected to see high demand for arthropod-borne viral infections testing over the forecast period. Implementation of stringent regulations to curb the spread of infectious diseases in this region is anticipated to drive market potential in these regions.
Densely populated countries like India and China are expected to emerge as highly lucrative markets for arthropod-borne viral infections testing vendors.
Rising instances of arboviral infections and epidemics in the MEA region are expected to majorly drive demand for arthropod-borne viral infections testing in this region. This region is expected to be one of the most important markets on a global level owing to the re-emergence of multiple infections like Zika virus and others.
Underdeveloped healthcare infrastructure is a major restraining factor for arthropod-borne viral infections testing market in the MEA region.
Principal Consultant
“Increasing Threat of Arboviral Infections Augmenting Market Expansion”
Instances of arthropod-borne viral infections have been increasing in the U.K. in recent times and this is anticipated to drive arthropod-borne viral infections testing demand in the nation. Lyme disease has become a prominent issue in the U.K. over recent years and other arthropod-borne diseases have also seen an increase in incidence.
Increasing global travel and trade are expected to fuel the adoption of arthropod-borne viral infections testing in the U.K.
“Developing Healthcare Infrastructure to Provide Lucrative Market Opportunities”
Brazil is anticipated to be a highly rewarding market for arthropod-borne viral infections testing vendors due to high incidence of multiple arthropod-borne viral infections like Zika virus and dengue. Brazil is a developing economy and has an emerging healthcare infrastructure that has a lot of untapped potential that arthropod-borne viral infections testing providers can unlock if they enter this market.
“High Preference for ELISA-based Test Kits to Drive Sales through 2029”
Enzyme-linked immunosorbent assay (ELISA)-based tests have been immensely popular in the arthropod-borne viral infections testing marketplace over the past few years and currently account for a dominant market share of 52% in the global landscape.
Increasing preference for use of ELISA-based test kits by patients, healthcare professionals, researchers, etc. is expected to propel its popularity further.
In 2022, reverse-transcription polymerase chain reaction (RT-PCR) kits hold a market share of 33.5% in the global arthropod-borne viral infections testing industry. The COVID-19 pandemic boosted demand for RT-PCR test kits and this trend is expected to be prevalent over the forecast period as well.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The COVID-19 pandemic invigorated demand for arthropod-borne viral infections testing and revolutionized our view on infectious diseases and infections. Increasing uncertainties in these diseases and their re-emergence are anticipated to play a major role in the coming years.
Sales of arthropod-borne viral infections testing kits dropped in 2020 as lockdown mandates were put in place and supply and logistic chains were disrupted. The market is expected to make a steady recovery in the post-pandemic era as restrictions are lifted across the world.
Arthropod-borne viral infections testing providers are investing in the research and development of rapid test kits that are effective in diagnosing infections in a short period of time with minimal error.
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2029 |
| Historical Data Available for | 2014 to 2021 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia & Pacific; Middle East & Africa (MEA) |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Germany, UK, France, Spain, Italy, China, Japan, South Korea, India, Indonesia, Malaysia, Singapore, Australia, New Zealand, Turkey, South Africa, and GCC Countries |
| Key Market Segments Covered | Test Type, End User, Region |
| Key Companies Profiled | Thermo Fisher Scientific Inc.; Roche Molecular Systems Inc.; bioMérieux SA; InBios International Inc.; NovaTec Immundiagnostica GmbH; Euroimmun AG (Sub. PerkinElmer); Quest Diagnostics; Certest Biotec S.L.; Response Biomedical Corp.; Chembio Diagnostic Systems Inc.; Abbott Laboratories |
| Pricing | Available upon Request |
Arthropod-borne Viral Infections Testing Market by Test Type:
Arthropod-borne Viral Infections Testing Market by End User:
Arthropod-borne Viral Infections Testing Market by Region:
The global arthropod-borne viral infections testing market holds a valuation of US$ 1.3 Bn in 2022.
ELISA-based tests account for 52% of the global arthropod-borne viral infections testing market share.
Demand for arthropod-borne viral infections testing is predicted to evolve at a CAGR of 5.6% from 2022 to 2029.
Sales of arthropod-borne viral infections testing kits are projected to reach US$ 1.9 Bn by 2029.
Leading arthropod-borne viral infections testing companies are Roche Molecular Systems Inc., bioMérieux SA, InBios International Inc., NovaTec Immundiagnostica GmbH, Euroimmun AG (Sub. PerkinElmer), Quest Diagnostics, Certest Biotec S.L., Response Biomedical Corp., Chembio Diagnostic Systems Inc., and Abbott Laboratories.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Technology Roadmap
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
3.3. Macro-Economic Factors
4. Key Success Factors
4.1. Product Adoption / Usage Analysis
4.2. Disease Epidemiology, By Key countries
4.3. Strategic Promotional Strategies
4.4. Regulatory Scenario
4.5. Opportunity Analysis
5. Global Arthropod-borne Viral Infections Testing Market Demand Analysis 2014-2021 and Forecast, 2022-2029
5.1. Historical Market Volume (Mn Units) Analysis, 2014-2021
5.2. Current and Future Market Volume (Mn Units) Projections, 2022-2029
5.3. Y-o-Y Growth Trend Analysis
6. Global Arthropod-borne Viral Infections Testing Market - Pricing Analysis
6.1. Regional Pricing Analysis By Test Type
6.2. Pricing Break-up
6.2.1. Manufacturer Level Pricing
6.2.2. Distributor Level Pricing
6.3. Global Average Pricing Analysis Benchmark
7. Global Arthropod-borne Viral Infections Testing Market Demand (in Value or Size in US$ Mn) Analysis 2014-2021 and Forecast, 2022-2029
7.1. Historical Market Value (US$ Mn) Analysis, 2014-2021
7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2029
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Market Background
8.1. Macro-Economic Factors
8.1.1. Global GDP Growth Outlook
8.1.2. Global Internet Penetration Outlook
8.1.3. Global Media and Entertainment Industry Outlook
8.2. Forecast Factors - Relevance & Impact
8.2.1. Top Companies Historical Growth
8.2.2. Global Healthcare Industry Outlook
8.2.3. Global GDP Growth Outlook
8.2.4. Research and Developmental Activities
8.2.5. Global Diagnostic Industry Outlook
8.3. Value Chain
8.4. Market Dynamics
8.4.1. Drivers
8.4.2. Restraints
8.4.3. Opportunity Analysis
9. Global Arthropod-borne Viral Infections Testing Market Analysis 2014-2021 and Forecast 2022-2029, by Test Type
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) and Volume Analysis By Test Type, 2014-2021
9.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast By Test Type, 2021 - 2021
9.3.1. ELISA-based Tests
9.3.2. RT-PCR based Tests
9.3.3. Immunochromatography Rapid Diagnosis
9.4. Market Attractiveness Analysis By Test Type
10.Global Arthropod-borne Viral Infections Testing Market Analysis 2014-2021 and Forecast 2022-2029, by End User
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) and Volume Analysis By End User, 2014-2021
10.3. Current and Future Market Size (US$ Mn) and Volume Analysis and Forecast By End User, 2021 - 2021
10.3.1. Hospitals
10.3.2. Public Health Laboratory
10.3.3. Diagnostic Centers
10.3.4. Others
10.4. Market Attractiveness Analysis By End User
11.Global Arthropod-borne Viral Infections Testing Market Analysis 2014-2021 and Forecast 2022-2029, by Region
11.1. Introduction
11.2. Historical Market Size (US$ Mn) and Volume Analysis By Region, 2014-2021
11.3. Current Market Size (US$ Mn) and Volume Analysis and Forecast By Region, 2021 - 2021
11.3.1. North America
11.3.2. Latin America
11.3.3. Europe
11.3.4. Middle East and Africa (MEA)
11.3.5. East Asia
11.3.6. South Asia
11.3.7. Oceania
11.4. Market Attractiveness Analysis By Region
12. North America Arthropod-borne Viral Infections Testing Market Analysis 2014-2021 and Forecast 2022-2029
12.1. Introduction
12.2. Pricing Analysis
12.3. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2014-2021
12.4. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2022-2029
12.4.1.By Country
12.4.1.1. U.S.
12.4.1.2. Canada
12.4.2. By Test Type
12.4.3. By End User
12.5. Market Attractiveness Analysis
12.5.1. By Country
12.5.2. By Test Type
12.5.3. By End User
12.6. Market Trends
12.7. Key Market Participants - Intensity Mapping
12.8. Drivers and Restraints - Impact Analysis
13. Latin America Arthropod-borne Viral Infections Testing Market Analysis 2014-2021 and Forecast 2022-2029
13.1. Introduction
13.2. Pricing Analysis
13.3. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2014-2021
13.4. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2022-2029
13.4.1.By Country
13.4.1.1. Brazil
13.4.1.2. Mexico
13.4.1.3. Rest of Latin America
13.4.2. By Test Type
13.4.3. By End User
13.5. Market Attractiveness Analysis
13.5.1. By Country
13.5.2. By Test Type
13.5.3. By End User
13.6. Market Trends
13.7. Key Market Participants - Intensity Mapping
13.8. Drivers and Restraints - Impact Analysis
14.Europe Arthropod-borne Viral Infections Testing Market Analysis 2014-2021 and Forecast 2022-2029
14.1. Introduction
14.2. Pricing Analysis
14.3. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2014-2021
14.4. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2022-2029
14.4.1.By Country
14.4.1.1. Germany
14.4.1.2. Italy
14.4.1.3. France
14.4.1.4. U.K.
14.4.1.5. Spain
14.4.1.6. BENELUX
14.4.1.7. Russia
14.4.1.8. Rest of Europe
14.4.2. By Test Type
14.4.3. By End User
14.5. Market Attractiveness Analysis
14.5.1. By Country
14.5.2. By Test Type
14.5.3. By End User
14.6. Market Trends
14.7. Key Market Participants - Intensity Mapping
14.8. Drivers and Restraints - Impact Analysis
15.South Asia Arthropod-borne Viral Infections Testing Market Analysis 2014-2021 and Forecast 2022-2029
15.1. Introduction
15.2. Pricing Analysis
15.3. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2014-2021
15.4. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2022-2029
15.4.1.By Country
15.4.1.1. India
15.4.1.2. Thailand
15.4.1.3. Indonesia
15.4.1.4. Malaysia
15.4.1.5. Rest of South Asia
15.4.2. By Test Type
15.4.3. By End User
15.5. Market Attractiveness Analysis
15.5.1. By Country
15.5.2. By Test Type
15.5.3. By End User
15.6. Market Trends
15.7. Key Market Participants - Intensity Mapping
15.8. Drivers and Restraints - Impact Analysis
16.East Asia Arthropod-borne Viral Infections Testing Market Analysis 2014-2021 and Forecast 2022-2029
16.1. Introduction
16.2. Pricing Analysis
16.3. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2014-2021
16.4. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2022-2029
16.4.1.By Country
16.4.1.1. China
16.4.1.2. Japan
16.4.1.3. South Korea
16.4.2. By Test Type
16.4.3. By End User
16.5. Market Attractiveness Analysis
16.5.1. By Country
16.5.2. By Test Type
16.5.3. By End User
16.6. Market Trends
16.7. Key Market Participants - Intensity Mapping
16.8. Drivers and Restraints - Impact Analysis
17.Oceania Arthropod-borne Viral Infections Testing Market Analysis 2014-2021 and Forecast 2022-2029
17.1. Introduction
17.2. Pricing Analysis
17.3. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2014-2021
17.4. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2022-2029
17.4.1.By Country
17.4.1.1. Australia
17.4.1.2. New Zealand
17.4.2. By Test Type
17.4.3. By End User
17.5. Market Attractiveness Analysis
17.5.1. By Country
17.5.2. By Test Type
17.5.3. By End User
17.6. Market Trends
17.7. Key Market Participants - Intensity Mapping
17.8. Drivers and Restraints - Impact Analysis
18.Middle East and Africa Arthropod-borne Viral Infections Testing Market Analysis 2014-2021 and Forecast 2022-2029
18.1. Introduction
18.2. Pricing Analysis
18.3. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2014-2021
18.4. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2022-2029
18.4.1. By Country
18.4.1.1. GCC Countries
18.4.1.2. Turkey
18.4.1.3. Northern Africa
18.4.1.4. South Africa
18.4.1.5. Rest of Middle East and Africa
18.4.2. By Test Type
18.4.3. By End User
18.5. Market Attractiveness Analysis
18.5.1. By Country
18.5.2. By Test Type
18.5.3. By End User
18.6. Market Trends
18.7. Key Market Participants - Intensity Mapping
18.8. Drivers and Restraints - Impact Analysis
19. Key and Emerging Countries Arthropod-borne Viral Infections Testing Market Analysis 2014-2021 and Forecast 2022-2029
19.1. Introduction
19.1.1. Market Value Proportion Analysis, By Key Countries
19.1.2. Global Vs. Country Growth Comparison
19.2. U.S. Arthropod-borne Viral Infections Testing Market Analysis
19.2.1. By Test Type
19.2.2. By End User
19.3. Canada Arthropod-borne Viral Infections Testing Market Analysis
19.3.1. By Test Type
19.3.2. By End User
19.4. Mexico Arthropod-borne Viral Infections Testing Market Analysis
19.4.1. By Test Type
19.4.2. By End User
19.5. Brazil Arthropod-borne Viral Infections Testing Market Analysis
19.5.1. By Test Type
19.5.2. By End User
19.6. U.K. Arthropod-borne Viral Infections Testing Market Analysis
19.6.1. By Test Type
19.6.2. By End User
19.7. Germany Arthropod-borne Viral Infections Testing Market Analysis
19.7.1. By Test Type
19.7.2. By End User
19.8. France Arthropod-borne Viral Infections Testing Market Analysis
19.8.1. By Test Type
19.8.2. By End User
19.9. Italy Arthropod-borne Viral Infections Testing Market Analysis
19.9.1. By Test Type
19.9.2. By End User
19.10. Spain Arthropod-borne Viral Infections Testing Market Analysis
19.10.1. By Test Type
19.10.2. By End User
19.11. BENELUX Arthropod-borne Viral Infections Testing Market Analysis
19.11.1. By Test Type
19.11.2. By End User
19.12. Russia Arthropod-borne Viral Infections Testing Market Analysis
19.12.1. By Test Type
19.12.2. By End User
19.13. China Arthropod-borne Viral Infections Testing Market Analysis
19.13.1. By Test Type
19.13.2. By End User
19.14. Japan Arthropod-borne Viral Infections Testing Market Analysis
19.14.1. By Test Type
19.14.2. By End User
19.15. South Korea Arthropod-borne Viral Infections Testing Market Analysis
19.15.1. By Test Type
19.15.2. By End User
19.16. India Arthropod-borne Viral Infections Testing Market Analysis
19.16.1. By Test Type
19.16.2. By End User
19.17. ASEAN Arthropod-borne Viral Infections Testing Market Analysis
19.17.1. By Test Type
19.17.2. By End User
19.18. Australia Arthropod-borne Viral Infections Testing Market Analysis
19.18.1. By Test Type
19.18.2. By End User
19.19. New Zealand Arthropod-borne Viral Infections Testing Market Analysis
19.19.1. By Test Type
19.19.2. By End User
19.20. GCC Countries Arthropod-borne Viral Infections Testing Market Analysis
19.20.1. By Test Type
19.20.2. By End User
19.21. Turkey Arthropod-borne Viral Infections Testing Market Analysis
19.21.1. By Test Type
19.21.2. By End User
19.22. South Africa Arthropod-borne Viral Infections Testing Market Analysis
19.22.1. By Test Type
19.22.2. By End User
20.Market Structure Analysis
20.1. Market Analysis by Tier of Companies (Arbovirus Testing)
20.2. Market Concentration
20.3. Market Share Analysis of Top Players
20.4. Market Presence Analysis
20.4.1. By Regional footprint of Players
20.4.2. Product foot print by Players
20.4.3. Channel Foot Print by Players
21.Competition Analysis
21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Competition Deep Dive
21.3.1. Thermo Fisher Scientific, Inc.
21.3.1.1. Overview
21.3.1.2. Product Portfolio
21.3.1.3. Profitability by Market Segments (Product/Channel/Region)
21.3.1.4. Sales Footprint
21.3.1.5. Strategy Overview
21.3.1.5.1. Marketing Strategy
21.3.1.5.2. Product Strategy
21.3.1.5.3. Channel Strategy
21.3.2. Roche Molecular Systems Inc.
21.3.2.1. Overview
21.3.2.2. Product Portfolio
21.3.2.3. Profitability by Market Segments (Product/Channel/Region)
21.3.2.4. Sales Footprint
21.3.2.5. Strategy Overview
21.3.2.5.1. Marketing Strategy
21.3.2.5.2. Product Strategy
21.3.2.5.3. Channel Strategy
21.3.3. bioMérieux SA
21.3.3.1. Overview
21.3.3.2. Product Portfolio
21.3.3.3. Profitability by Market Segments (Product/Channel/Region)
21.3.3.4. Sales Footprint
21.3.3.5. Strategy Overview
21.3.3.5.1. Marketing Strategy
21.3.3.5.2. Product Strategy
21.3.3.5.3. Channel Strategy
21.3.4. Abbott Laboratories
21.3.4.1. Overview
21.3.4.2. Product Portfolio
21.3.4.3. Profitability by Market Segments (Product/Channel/Region)
21.3.4.4. Sales Footprint
21.3.4.5. Strategy Overview
21.3.4.5.1. Marketing Strategy
21.3.4.5.2. Product Strategy
21.3.4.5.3. Channel Strategy
21.3.5. InBios International, Inc.
21.3.5.1. Overview
21.3.5.2. Product Portfolio
21.3.5.3. Profitability by Market Segments (Product/Channel/Region)
21.3.5.4. Sales Footprint
21.3.5.5. Strategy Overview
21.3.5.5.1. Marketing Strategy
21.3.5.5.2. Product Strategy
21.3.5.5.3. Channel Strategy
21.3.6. NovaTec Immundiagnostica GmbH
21.3.6.1. Overview
21.3.6.2. Product Portfolio
21.3.6.3. Profitability by Market Segments (Product/Channel/Region)
21.3.6.4. Sales Footprint
21.3.6.5. Strategy Overview
21.3.6.5.1. Marketing Strategy
21.3.6.5.2. Product Strategy
21.3.6.5.3. Channel Strategy
21.3.7. Euroimmun AG (Sub. PerkinElmer)
21.3.7.1. Overview
21.3.7.2. Product Portfolio
21.3.7.3. Profitability by Market Segments (Product/Channel/Region)
21.3.7.4. Sales Footprint
21.3.7.5. Strategy Overview
21.3.7.5.1. Marketing Strategy
21.3.7.5.2. Product Strategy
21.3.7.5.3. Channel Strategy
21.3.8. Quest Diagnostics
21.3.8.1. Overview
21.3.8.2. Product Portfolio
21.3.8.3. Profitability by Market Segments (Product/Channel/Region)
21.3.8.4. Sales Footprint
21.3.8.5. Strategy Overview
21.3.8.5.1. Marketing Strategy
21.3.8.5.2. Product Strategy
21.3.8.5.3. Channel Strategy
21.3.9. Certest Biotec S.L.
21.3.9.1. Overview
21.3.9.2. Product Portfolio
21.3.9.3. Profitability by Market Segments (Product/Channel/Region)
21.3.9.4. Sales Footprint
21.3.9.5. Strategy Overview
21.3.9.5.1. Marketing Strategy
21.3.9.5.2. Product Strategy
21.3.9.5.3. Channel Strategy
21.3.10. Response Biomedical Corp.
21.3.10.1. Overview
21.3.10.2. Product Portfolio
21.3.10.3. Profitability by Market Segments (Product/Channel/Region)
21.3.10.4. Sales Footprint
21.3.10.5. Strategy Overview
21.3.10.5.1. Marketing Strategy
21.3.10.5.2. Product Strategy
21.3.10.5.3. Channel Strategy
21.3.11. Chembio Diagnostic Systems, Inc.
21.3.11.1. Overview
21.3.11.2. Product Portfolio
21.3.11.3. Profitability by Market Segments (Product/Channel/Region)
21.3.11.4. Sales Footprint
21.3.11.5. Strategy Overview
21.3.11.5.1. Marketing Strategy
21.3.11.5.2. Product Strategy
21.3.11.5.3. Channel Strategy
22.Assumptions and Acronyms Used
23. Research Methodology
Explore Healthcare Insights
View Reports
Arthropod-borne Viral Infections Testing Market
